SFARI launched a request for applications in early 2015 that sought proposals to develop medium- and high-throughput screens to test the functional effects of de novo missense variants identified in the Simons Simplex Collection and other autism cohorts. Here, SFARI Senior Scientist Alan Packer discusses the proposals that were selected for funding as well as highlighting recent papers that have provided functional evidence for missense variants contributing to autism and other disorders.
Today, we’re announcing our annual request for applications (RFA) for SFARI Pilot and Research Awards. Letters of intent (LOIs), the short statements that precede full applications, are due no later than 9 October, 2015. As we do every year, we’ve updated this column to provide a better picture of how the SFARI science team makes decisions on research proposals.
On 2 September, we plan to announce a new request for applications. Letters of intent, the short statements that precede full applications, are due no later than 10 October. It seems timely, therefore, to describe how we make decisions on research proposals.
SFARI’s chief scientist, Gerald Fischbach, provides an overview of what we know and what we need to learn about autism and related developmental disorders. We hope this article will serve as a valuable resource for experts in autism research and also as a helpful guide for those just entering the field.
Today, we’re announcing a new request for applications. Letters of intent, the short statements that precede full applications, are due no later than 11 October. It seems timely, therefore, to describe how we make decisions on research proposals.
A number of autism risk factors converge on one cellular pathway: abnormal remodeling of the cell's structural systems through the signaling protein Rho, says SFARI’s associate director for research, Alan Packer.
Which grant applications should SFARI choose to fund each year? The principles that guide that decision are nuanced and evolve as new results emerge. But there are some clear general guidelines in place, says John Spiro, SFARI’s deputy scientific director.
New genetic variants that increase susceptibility to autism are emerging at a rapid pace. Given the profusion of data, it seems timely to assess the availability and usefulness of mouse models in which to study these genetic risk factors.